We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Inhibition of Polarity Protein Gene Triggers Cancer-Like Changes in Cell Shape

By LabMedica International staff writers
Posted on 02 Jul 2009
Researchers have identified a gene linked to the mechanism that determines cell shape and have shown how its lack characterizes certain types of cancer cells.

Investigators from the University of Virginia (Charlottesville, USA) used a novel shRNA lentiviral system to manipulate gene expression in mouse mammary stem/progenitor cells. More...
The shRNA specifically inhibited expression of the protease activated receptor 3 (PAR3) gene. This gene encodes a polarity protein that controls how cells acquire particular shapes, so that they have a top and a bottom.

Results published in the June 15, 2009, issue of the journal Genes & Development revealed that transplantation of Par3-depleted stem/progenitor cells into the mammary fat pad severely disrupted mammary development. The investigators identified a novel function for the atypical protein kinase C (aPKC)-binding domain of Par3 in restricting Par3 and aPKC to the apical region of mammary epithelia in vivo, and found that mammary morphogenesis was dependent on the ability of Par3 to directly bind aPKC.

These results revealed a new function for Par3 in the regulation of progenitor differentiation and epithelial morphogenesis in vivo and demonstrated for the first time an essential requirement for the Par3–aPKC interaction.

"A big problem in biology is that there are many thousands of genes. Testing the function of any one of them in a living organism, such as a mouse, has traditionally been slow and very expensive,” said senior author Dr. Ian Macara, professor of microbiology at the University of Virginia. "The new technology is hundreds of times cheaper and many times faster than traditional approaches. While we used it to study the function of a specific breast-developing gene, our method can be replicated in screening for genes that can suppress tumors or cause cancer.”

Related Links:

University of Virginia




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.